Steven Cohen’s Standard BioTools LAB Stock Holding History

Steven Cohen’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$582K	Buy	707,991 +663,270	+1,483%	+$627K	﹤0.01%	3108
2026 Q1	$41.1K	Sell	44,721 -98,586	-69%	-$119K	﹤0.01%	3670
2025 Q4	$183K	Buy	+143,307	New	+$193K	﹤0.01%	3658
2024 Q2	–	Sell	-142,300	Closed	-$386K	–	2174
2024 Q1	$386K	Buy	+142,300	New	+$344K	﹤0.01%	1710
2023 Q4	–	Sell	-34,582	Closed	-$100K	–	2498
2023 Q3	$100K	Buy	+34,582	New	+$90.4K	﹤0.01%	1967
2020 Q3	–	Sell	-399,415	Closed	-$1.6M	–	1012
2020 Q2	$1.6M	Buy	+399,415	New	+$1.39M	0.01%	626
2015 Q3	–	Sell	-63,400	Closed	-$1.53M	–	844
2015 Q2	$1.53M	Buy	+63,400	New	+$2M	0.01%	590

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Steven Cohen's LAB Position: Q2 2026 in Review

Steven Cohen increased its Standard BioTools (LAB) stake by 1,483% in Q2 2026, buying an estimated $627K and bringing the position to 707,991 shares worth $582K. The position accounts for ﹤0.01% of the portfolio, ranked #3108.

Steven Cohen first reported a position in LAB in Q2 2015 and has held it in 7 quarters since. The position peaked at $1.6M in Q2 2020. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Steven Cohen held 707,991 shares of Standard BioTools worth $582K as of Q2 2026.
Steven Cohen bought 663,270 Standard BioTools shares in Q2 2026, an estimated $627K.
Standard BioTools made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #3108 holding.
Steven Cohen first reported a position in Standard BioTools in Q2 2015 and has held it in 7 quarters since.
Steven Cohen's Standard BioTools position peaked at $1.6M in Q2 2020.
143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.